Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Patent Win For Sofosbuvir In India But "Tortured" Ruling Faces Appeal

Executive Summary

India has approved a Gilead Sciences Inc. patent that claims the active metabolites of sofosbuvir amid allegations by opponents of "external pressures" on the patent office and that the decision "weakens" Section 3(d) of India's patent regulation.


Related Content

Court points to 'para lifts', potential for bias in Indian Sovaldi case
Cut price generics in sight as Gilead licenses Sovaldi
Novartis sees India Glivec ruling indicative of IP 'de-recognition'